Impact of immunosuppressants on SARS-CoV-2 infection in elderly patients with inflammatory bowel disease.
Aging Clin Exp Res
; 33(8): 2355-2359, 2021 Aug.
Article
in English
| MEDLINE | ID: covidwho-1491492
ABSTRACT
BACKGROUND:
Older age has been reported as a risk factor for severe SARS-CoV-2 disease (COVID-19). The impact of immunosuppressants (IMS) on COVID-19 is still under debate.AIM:
To describe the incidence and severity of COVID-19 in elderly patients with inflammatory bowel disease (IBD) in relation to the use of IMS.METHODS:
IBD patients over 65 years of age were selected and grouped in terms of IMS use. Confirmed COVID-19, adherence to IST, comorbidities and concomitant non-IBD-related treatments between 1st of March 2020 to 1st of March 2021 were recorded.RESULTS:
Out of 418 patients included, 89 (21.3%) were on IMS. Thirty-two patients (7.7%) had COVID-19, 7 of whom were on IMS (7.6% not on IMS vs. 7.9% on IMS; P = 0.933) and 7 (22%) patients died.CONCLUSIONS:
Incidence of COVID-19 among elderly IBD patients was similar to that reported in the background population, regardless of the use of IMS.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Inflammatory Bowel Diseases
/
COVID-19
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
Limits:
Aged
/
Humans
Language:
English
Journal:
Aging Clin Exp Res
Journal subject:
Geriatrics
Year:
2021
Document Type:
Article
Affiliation country:
S40520-021-01917-9
Similar
MEDLINE
...
LILACS
LIS